1. Flow cytometric analysis of anti-c-MET CAR expression. 293 cells were lentivirally transduced with anti-c-MET CAR. Flow cytometric analysis was performed with a negative control protein and HGFR/c-Met Protein, Human, Recombinant (His), AF488-Labeled (Cat#TMPY-07026), respectively. Non-transduced 293 cells were used as a control (left).
2. Binding activity of AF 488-conjugated c-MET protein to PBMC cells. PBMC cells were stained with anti-CD3 antibody and HGFR/c-Met Protein, Human, Recombinant (His), AF488-Labeled (Cat#TMPY-07026) and detected by flow cytometry. PBMC cells stained with anti-CD3 antibody were used as a control (left).

HGFR/c-Met Protein, Human, Recombinant (His), AF488-Labeled is expressed in HEK293 Cells. The accession number is P08581-1.

≥ 90% as determined by SDS-PAGE.

Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR protein is produced as a single-chain precursor, and HGF is the only known ligand. Normal HGF/HGFR signaling is essential for embryonic development, tissue repair, or wound healing, whereas aberrantly active HGFR has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. HGFR protein is a multifaceted regulator of growth, motility, and invasion, and is normally expressed by cells of epithelial origin. Preclinical studies suggest that targeting aberrant HGFR signaling could be an attractive therapy in cancer.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy